What is the drug of choice for lowering VLDL levels in patients at risk of pancreatitis and for mixed elevations of LDLs and VLDLs and low levels of HDLs?Question 3Answera.Ezetimibeb.Fibric Acidsc.Statinsd.Niacine.Bile acid-binding resinsClear my choice

To determine the drug of choice for lowering VLDL levels in patients at risk of pancreatitis and for mixed elevations of LDLs and VLDLs and low levels of HDLs, let's analyze each option:

a. Ezetimibe: This drug primarily lowers LDL cholesterol by inhibiting the absorption of cholesterol in the small intestine. It is not the first choice for lowering VLDL levels or addressing mixed dyslipidemia.

b. Fibric Acids: These drugs, also known as fibrates, are effective in lowering VLDL levels and triglycerides. They also help increase HDL levels. Fibrates are often used in patients with hypertriglyceridemia and mixed dyslipidemia, making them a suitable choice for the given conditions.

c. Statins: Statins are primarily used to lower LDL cholesterol levels. While they have some effect on lowering triglycerides and raising HDL levels, they are not the first choice for specifically lowering VLDL levels.

d. Niacin: Niacin (vitamin B3) can lower VLDL and LDL levels and raise HDL levels. It is effective in treating mixed dyslipidemia, but it is not typically the first-line treatment due to its side effect profile.

e. Bile acid-binding resins: These drugs primarily lower LDL cholesterol by binding bile acids in the intestine. They are not effective in lowering VLDL levels or treating mixed dyslipidemia.

Based on the analysis, the most appropriate choice for lowering VLDL levels in patients at risk of pancreatitis and for mixed elevations of LDLs and VLDLs and low levels of HDLs is:

b. Fibric Acids